The Power of Partnerships: Why Pharma Needs to Redefine its Role With IDNs

July 24, 2021

Large healthcare conglomerates, or integrated delivery networks (IDNs), have long been fixtures in the market access landscape—a dynamic that has gone unchanged despite the disruption caused by COVID-19. While M&A activity slowed down during 2020 , IDNs are seeing a bout of positive recognition: Many have received accolades on their ability to deliver quality coordinated care during a year of upheaval for healthcare.

Read the source article at Welcome
2021-07-19 18:11:42

Share This Story!